Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates Exagen (XGN) delivered earnings and revenue surprises of +29.17% and +4.57%, respectively, for the quarter ended March 2026. Do the…
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume CARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing…
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights Delivered record full-year total revenue and AVISE CTD average selling priceImproved full-year adjusted EBITDA loss and cash use by over…
Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance CARLSBAD, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing…
Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference CARLSBAD, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions,…
Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing…
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates Exagen (XGN) delivered earnings and revenue surprises of 52.50% and 9.21%, respectively, for the quarter ended March 2024. Do the…
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results CARLSBAD, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions,…
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates Exagen Inc. (XGN) delivered earnings and revenue surprises of 24.39% and 20.40%, respectively, for the quarter ended December 2023. Do…